Obesity market shifts: pricing and delivery innovation

Novo Nordisk and Eli Lilly already won the first round of the obesity-drug race by making weekly shots into blockbusters. The new fight is over who can cut prices, switch patients into pills, and keep spending on the next decade before today’s margins get squeezed. (novonordisk.com) (insilico.com) India is where that pressure shows up fastest because local drugmakers can sell far cheaper copies. Reuters reported on March 31, 2026 that Novo Nordisk cut Indian prices on Ozempic by up to 36% and on Wegovy by up to 48% to defend share against low-cost semaglutide rivals. (reuters.com) That matters because Eli Lilly got to India’s obesity market early with Mounjaro and built a lead before Novo fully ramped up. Reuters reported in 2025 that Novo had already cut Wegovy prices in India by as much as 37% to chase Lilly in a market analysts saw as a key test for global obesity-drug demand. (reuters.com) The second front is not cheaper shots but easier delivery. Novo Nordisk said on February 25, 2026 that it signed a partnership with Vivtex worth up to 2.1 billion dollars to develop next-generation oral medicines for obesity and diabetes. (novonordisk.com) An oral biologic is a protein drug in a pill, which is hard because stomach acid usually destroys proteins the way rain ruins paper. Novo’s bet is that if patients can swallow a tablet instead of storing pens and injecting every week, the market gets bigger even if each prescription earns less. (novonordisk.com) Novo is pushing that route in public already. On April 2, 2026, the company said its Wegovy pill showed greater weight loss than Eli Lilly’s oral candidate orforglipron in an indirect comparison presented for the Obesity Medicine Association 2026 meeting. (novonordisk.com) Lilly is answering with a different kind of platform bet. On March 29, 2026, Insilico Medicine said Lilly expanded its artificial-intelligence drug discovery work into a collaboration worth about 2.75 billion dollars, including 115 million dollars upfront and milestone payments tied to future programs. (insilico.com) Artificial intelligence drug discovery is software that searches through huge chemical haystacks for a few useful needles. Lilly’s idea is that faster target-finding and molecule design can feed new products into obesity, diabetes, and neuroscience before rivals catch up on today’s injected drugs. (insilico.com) Novo’s move says the weekly-shot business will not stay premium forever. Lilly’s move says the company expects that pressure and wants more ways to invent the next hit, even if those bets take years and billions before they show up in sales. (reuters.com) (insilico.com) So the obesity market is starting to look less like a simple land grab and more like the smartphone business after the first boom. The easy money came from selling the must-have device, and the harder money comes from cutting prices, improving convenience, and building the next operating system before the first one matures. (reuters.com) (novonordisk.com)